WinstonWınston
Back

Deep Value: cash covers more than 100% of the stock price

This company holds roughly $6M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Integrated BioPharma logo

Integrated BioPharma

INBP
16
Medical - Pharmaceuticals · Healthcare
Price
$0.18
+0.00 (+0.00%)
Market Cap
$5.6M
Winston Score
16
Winston is worried
Weak fundamentals across most pillars.
Data as of Aug 23, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Weak
Growth
Weak
Cash Flow
Weak
Stability
Data not available
Valuation
Data not available

Share count falling — buybacks

2.9% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 32.1M (2021) → 31.2M (2025)

Winston Score History

The full picture

Integrated BioPharma is a company that makes nutritional supplements and vitamins. Its products include vitamins, minerals, herbal supplements, and sports nutrition items sold under several brand names. The company sells to retailers, health food stores, and consumers, placing it in the broader packaged health and wellness industry.

The company earns money by manufacturing and selling these supplement products, operating primarily in the United States. With a market cap near zero and negative operating margins, the business has faced serious financial difficulties, including past bankruptcy proceedings. The core risk here is the company's weak financial position — razor-thin gross margins of around 5% leave almost no room for error, and the business has struggled to generate consistent profits in a crowded supplement market where larger, better-funded competitors have significant advantages in distribution and brand recognition.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-27.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-233.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

69.9%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$6M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Integrated BioPharma's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
-2.7%
Thin — -2.7% gross margin
Profit after running costs
Operating Margin
-10.7%
Losing money on operations — -10.7%
Return on the money invested
ROCE
-6.6%
Weak — -6.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-8.8%
Shrinking sales (-8.8% YoY)
Profit growth
EPS YoY
-228.4%
Earnings shrinking (-228.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
5.9%
Thin free cash flow (5.9%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial